Phase I study of iproplatin in pediatric patients: a Pediatric Oncology Group Study.
Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose-limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007223:Infant; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D009944:Organoplatinum Compounds; C023359:iproplatin